Search Results
Your search for ,USE matches 11258 pages
Showing 2001 - 2050Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes
After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...
Expert Point of View: Natasha Leighl, MD
“CodeBreaK 200 clearly establishes sotorasib as the new standard of care, replacing docetaxel as second- or third-line therapy for advanced KRAS G12C–mutated lung cancer,” stated invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto. “Sotorasib improved...
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 106,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people over the age of 50 years, which is ...
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
Highlights From the ESMO Congress 2022
At this year’s European Society for Medical Oncology (ESMO) Congress, we experienced an eagerly awaited return to normality (or almost), and the quality of the science on display was anything but disappointing: from molecular medicine to treatment de-escalation, from early cancer detection and...
Chemotherapy Outcomes in Noninfant Childhood ALL With 11q23/KMT2A Rearrangements
In a retrospective study reported in the Journal of Clinical Oncology, Attarbaschi et al described outcomes in patients with noninfant childhood acute lymphoblastic leukemia (ALL) and 11q23/KMT2A rearrangements treated with chemotherapy regimens between 1995 and 2010. Study Details The study...
Legal and Ethical Use of Complementary and Alternative Medicine Interventions in Oncology
In addition to, or instead of, receiving therapies that are the standard of care, patients with cancer sometimes request to receive complementary (therapies used in conjunction with standard cancer treatment) and alternative (nonstandard treatments used in place of standard cancer treatment)...
Neoadjuvant Immunotherapy With Relatlimab and Nivolumab in Stage III Melanoma
The combination of immune checkpoint inhibitors relatlimab and nivolumab for patients with stage III melanoma given before surgery was safe and completely cleared all viable tumor in 57% of patients in a phase II study, according to findings published by Amaria et al in Nature. In addition to...
Phase II Trial Reports High Response Rates With Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, almost two-thirds of patients with stage II to IV cutaneous squamous cell carcinoma had tumors nearly or completely eradicated by neoadjuvant treatment with cemiplimab-rwlc, an agent targeting PD-1. The results were presented at the European ...
Analysis of Radiotherapy and Breast Cancer Recurrence in the RxPONDER Trial
Do patients with breast cancer and a low 21-gene recurrence score need regional node irradiation to reduce their risk of locoregional recurrence? An analysis of RxPONDER trial data suggests only a randomized clinical trial devoted to this question can provide a decisive answer. An analysis of data...
Multimodal Artificial Intelligence Models May Offer an Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer
NRG Oncology investigators analyzed clinical and digital histopathology data from five phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multimodal artificial intelligence models (MMAI) that could outperform the National Comprehensive Cancer...
Have Changes in Cancer Therapy Over Time Affected the Risk of Breast Cancer Among Female Childhood Cancer Survivors?
In an analysis from the Childhood Cancer Survivor Study reported in JAMA Oncology, Tara O. Henderson, MD, MPH, and colleagues found that rates of invasive breast cancer have declined over time among female survivors of childhood cancer, with the reduction appearing to be largely associated with...
AACR and ASCO Release Joint Policy Statement on Electronic Nicotine Delivery Systems
The American Association for Cancer Research (AACR) and ASCO have released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The...
Response-Adapted Ultra–Low Dose Radiation Achieves Complete Response in Majority of Patients With Orbital Indolent B-Cell Lymphomas
Using a novel response-adapted ultra–low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphomas. Results were presented by Pinnix et al at the 2022 American Society...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Austria
The Republic of Austria is a high-income, landlocked country in south-central Europe and has been a member of the European Union since 1995.1 Vienna, the capital city of nearly 2 million people, is regularly ranked among the most livable cities in the world.2 The total population of Austria is more ...
A Urologic Surgeon Shares His Insights on Robotic Radical Prostatectomy
In 2000, the da Vinci Surgical System broke new ground by becoming the first robotic surgery system approved by the U.S. Food and Drug Administration for general laparoscopic surgery. In its early years, robot-assisted radical prostatectomy was characterized by some in the surgical community as an...
Novel Selective Estrogen Receptor Degraders in Advanced Breast Cancer: Use of Elacestrant in the Phase III EMERALD Trial
Endocrine therapy is the foundation of first-line therapy in most patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Many of these patients respond to endocrine therapy but eventually become resistant to it through both intrinsic and acquired resistance mechanisms....
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
SIO-ASCO Guideline Proposes Evidence-Based Approaches to Pain Management Incorporating Integrative Medicine Interventions
The Society for Integrative Oncology (SIO) and ASCO have released a guideline that appraises the evidence to support incorporating integrative medicine approaches into managing pain in adults with cancer.1 The guideline builds upon existing ASCO guidelines on pain management, the growing body of...
Richter Transformation Remains Challenging, but Better Treatments Are on the Horizon
Richter transformation, usually a diffuse large B-cell lymphoma developing in a person with CLL, remains a challenging entity, but novel regimens look promising, as described at the 2022 Pan Pacific Lymphoma Conference by Matthew S. Davids, MD, MMSc, Associate Professor of Medicine at Harvard...
Expert Point of View: Bernard Escudier, MD and Brian I. Rini, MD
To put the CheckMate 914, IMmotion010, and PROSPER trials into context, The ASCO Post spoke with Bernard Escudier, MD, former Chair of the Genitourinary Group of the Institut Gustave Roussy, Villejuif, France. In general, Dr. Escudier believes that studies to date are not robust enough to justify...
A Call for Creativity: The Shades of Gray in Delivery of Goal-Concordant Care
I continue to be struck by the creativity of medical oncologists. The reimagining of dosing, duration, or regimen composition to respond to patient symptoms or preferences is like a master chef in the kitchen. Although standardization has, with good reason, become the paragon, delivering...
Why Are Young Adult Women Developing Later-Stage, More Aggressive Breast Cancer Than Older Women?
It has been well documented that breast cancer is the most common malignancy in adolescent and young adult (AYA) women aged 15 to 39 years, accounting for 30% of cancers among this population.1 In addition, 5.6% of all invasive breast cancers occur in AYA women.1 A presentation by Rebecca H....
Small First-in-Human Trial Investigates FLASH Proton Radiotherapy for Patients With Bone Metastases
FLASH radiation treatment—which delivers therapeutic doses of radiation in a fraction of a second—may be a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests. The technology, previously tested in animals, was shown to be as...
AI Model Using Daily Step Counts May Help Predict Unplanned Hospitalizations During Cancer Therapy
An artificial intelligence (AI) model developed by researchers may assist in predicting the likelihood that a patient may have an unplanned hospitalization during radiation treatments for cancer. The machine-learning model uses daily step counts as a proxy to monitor patients’ health as they go...
Effect of Goals-of-Care Program for Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic
As reported in the Journal of Clinical Oncology by David Hui, MD, MSc, and colleagues, an interdisciplinary goals-of-care program instituted at The University of Texas MD Anderson Cancer Center in response to anticipated COVID-19–related increases in need for intensive care unit (ICU) use resulted ...
Hair-Straightening Chemicals May Be Associated With Higher Uterine Cancer Risk
Individuals who reported using chemical hair-straightening products may be at greater risk for uterine cancer compared to those who did not report using these products, according to a new study published by Chang et al in the Journal of the National Cancer Institute (JNCI). The researchers found no ...
Use of Remote Interventions Increased Adherence to Cancer Screenings Among Women in Rural Areas
Studies show that rural populations experience greater cancer disparities across the cancer control continuum—from prevention and incidence to survivorship and mortality—compared with their urban counterparts. Those living in rural parts of the United States also tend to have lower cancer screening ...
Silicone-Based Polyurethane Film May Reduce Acute Radiation Dermatitis in Patients With Breast Cancer
Mepitel Film—a silicone-based polyurethane film dressing—may be beneficial in reducing skin toxicities caused by radiation treatment, according to data presented during the October 2022 session of the ASCO Plenary Series by Chow et al (Abstract 390226). Results of the phase III trial showed the...
Study Examines Efficacy, Cost of FIT vs Multitarget Stool DNA Testing for Colorectal Cancer Screening
Commercially available noninvasive screening tests for colorectal cancer—the fecal immunochemical test (FIT) and the Cologuard multitarget stool DNA test—are equally effective for screening patients with early-stage colorectal cancer. However, FIT costs about one-fifth of the multitarget stool DNA...
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, first-line treatment with ribociclib plus fulvestrant added nearly 16 months of overall survival time vs fulvestrant...
Breast Cancer 2021–2022 Almanac
The past year has seen an unprecedented number of practice-changing advances across all three major breast cancer subtypes. For patients with early-stage triple-negative breast cancer, neoadjuvant chemotherapy plus pembrolizumab firmly entered the standard of care based on improvements in...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
Expert Point of View: Amy Tiersten, MD and Carlos L. Arteaga, MD
Amy Tiersten, MD, Professor of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, and Carlos L. Arteaga, MD, Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology at The University of Texas Southwestern Medical Center, Dallas,...
Dual Checkpoint Inhibitor Therapy Elicits Responses in Highly Mutated Breast Cancer
Patients with advanced HER2-negative metastatic breast cancer and high tumor mutational burden achieved responses—often durable—from treatment with the immunotherapy doublet of nivolumab and ipilimumab, according to results of the phase II NIMBUS trial reported at the 2021 San Antonio Breast Cancer ...
Expert Point of View: Mark E. Robson, MD
“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...
EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer
Use of the first investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly reduced the risk of death or disease progression and lengthened progression-free survival compared with standard-of-care endocrine therapy with fulvestrant or an aromatase inhibitor in...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Computer Platform May Help Match Patients With Cancer to Targeted Therapy Trials
As more patients with cancer have their tumors genomically profiled and more therapies targeting genomic alterations enter clinical trials, the task of connecting patients with trials for which they are eligible can be especially challenging. The novel computer platform MatchMiner, developed by the ...
Polycystic Ovary Syndrome and Risk of Pancreatic Cancer
In a single-center case-control study reported as a research letter in JAMA Oncology, Peeri et al found that women with polycystic ovary syndrome (PCOS) may be at an increased risk of developing pancreatic cancer. Study Details The study involved data from the Memorial Sloan Kettering Cancer Center ...
Risk of Meningioma in Childhood Cancer Survivors
In a pooled analysis reported in JAMA Oncology, Withrow et al found that increased exposure of the meninges to radiation therapy was associated with an increased risk of developing meningioma in survivors of childhood cancer. Receipt of methotrexate was also associated with increased risk. Study...
Palliative Care Use Among Commercially Insured U.S. Patients With Metastatic Cancer: 2001–2016
In a study reported in JCO Oncology Practice, Ferrario et al found that while use of palliative care among commercially insured patients aged 25 to 64 years in the United States with metastatic cancer has increased since 2001, use remained at 40% among patients with very poor–prognosis cancers in...
Nivolumab/Ipilimumab vs Dabrafenib/Trametinib With Switch at Disease Progression for Metastatic BRAF-Mutant Melanoma
As reported in the Journal of Clinical Oncology by Michael B. Atkins, MD, and colleagues, the phase III DREAMseq trial (ECOG-ACRIN EA6134) showed that first-line treatment with nivolumab plus ipilimumab followed at disease progression with dabrafenib and trametinib improved 2-year overall survival...
Impact of CDC Opioid-Prescribing Guideline on Prescriptions and Potential Misuse/Substance Use Disorder Among Childhood Cancer Survivors
In a study reported in JAMA Oncology, Hu et al found decreases in the rates of opiate prescription and potential misuse/substance use disorders among survivors of childhood cancer following the March 2016 release of the Centers for Disease Control and Prevention (CDC) opioid-prescribing guideline....
RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy
The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...
Ibrutinib for Pediatric Patients With Chronic Graft-vs-Host Disease
On August 24, 2022, ibrutinib was approved for pediatric patients 1 year of age or older with chronic graft-vs-host disease after failure of one or more lines of systemic therapy.1 A new oral suspension formulation is available. Supporting Efficacy Data Approval was based on findings from the...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
First-Line Maintenance With Olaparib Improved Overall Survival in Subsets of Patients With Advanced Ovarian Cancer in Two Phase III Trials
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2022 Congress.1,2 In the SOLO1 trial,1 more...
